COMP <GO>
NRC vs ABBV // RETURN ON INVESTED CAPITAL (ROIC)
NRC Health (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: NRC 4
— ABBV 8
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: ABBV
LAST: $23.49 (+0.09%) • MKT CAP: $519.6M
roic
21.00%
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
roic
29.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NRC VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NRC | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 70.20% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 21.00% | 29.00% | -8.00 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 18.6x | 33.3x | -14.70 | NRC | /valuation <GO> |
| Free Cash Flow Yield | 3.03% | 3.47% | -0.44 | ABBV | /fcf-yield <GO> |
| Operating Margin | 16.40% | 24.60% | -8.20 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 8.40% | 6.90% | +1.50 | NRC | /net-margins <GO> |
| Revenue Growth (YoY) | -4.00% | 8.60% | -12.60 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.11% | 2.27% | -0.16 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.82 | 5.33 | -1.51 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 7/9 | -3.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 66.7 | 65.1 | +1.59 | NRC | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 41.7x | 113.1x | -71.40 | NRC | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $519.6M | $513.86B | -$513.34B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NRC REV | ABBV REV | NRC GROSS % | ABBV GROSS % | NRC FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $137.4M | $61.16B | — | 70.2% | $15.7M | $17.82B |
| FY 2024 | $143.1M | $56.33B | — | 70.0% | $19.2M | $17.83B |
| FY 2023 | $148.6M | $54.32B | — | — | $38.1M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NRC // BETA —
ABBV // BETA 1.15